Literature DB >> 15968092

Plasma cell labeling index.

Philip R Greipp1, Shaji Kumar.   

Abstract

Multiple myeloma is characterized by proliferation of monoclonal plasma cells (PCs), mostly in the bone marrow. The proliferative rate of the malignant plasma cell is an important determinant of the disease biology and can be measured as the percentage of PCs in the S-phase of the cell cycle. This percentage, or PC labeling index, can be measured using a slide-based immunofluorescence method using an antibody against 5-bromo-2'-deoxyuridine, which is actively incorporated by DNA of the dividing PCs. This technique, which can be performed using bone marrow or peripheral blood specimens, also utilizes concurrent cytoplasmic staining against immunoglobulin as well as kappa and lambda light chains. Employment of cytoplasmic immunoglobulin staining allows more specific identification of PCs as well as confirmation of the monoclonal nature of the PC population. The staining procedure, which can be done manually or using an automated stainer, as well as the process of reading and interpreting these slides is described in detail. The bone marrow peripheral blood labeling index is an important clinical test, providing valuable diagnostic and prognostic information.

Entities:  

Mesh:

Year:  2005        PMID: 15968092     DOI: 10.1385/1-59259-916-8:25

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  17 in total

1.  Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.

Authors:  Shaji K Kumar; Martha Q Lacy; Angela Dispenzieri; Francis K Buadi; Suzanne R Hayman; David Dingli; Francesca Gay; Shirshendu Sinha; Nelson Leung; William Hogan; S Vincent Rajkumar; Morie A Gertz
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 2.  How best to use new therapies in multiple myeloma.

Authors:  David Dingli; S Vincent Rajkumar
Journal:  Blood Rev       Date:  2010-04-01       Impact factor: 8.250

3.  Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.

Authors:  Sumit Madan; Robert A Kyle; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

4.  Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Authors:  D K Walters; X Wu; R C Tschumper; B K Arendt; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

5.  Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.

Authors:  Patrick W Mellors; Moritz Binder; Rhett P Ketterling; Patricia T Greipp; Linda B Baughn; Jess F Peterson; Dragan Jevremovic; Kathryn E Pearce; Francis K Buadi; Martha Q Lacy; Morie A Gertz; Angela Dispenzieri; Suzanne R Hayman; Prashant Kapoor; Wilson I Gonsalves; Yi L Hwa; Amie Fonder; Miriam Hobbs; Taxiarchis Kourelis; Rahma Warsame; John A Lust; Nelson Leung; Ronald S Go; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Blood Adv       Date:  2020-05-26

6.  Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.

Authors:  Zachary J Walker; Michael J VanWyngarden; Brett M Stevens; Diana Abbott; Andrew Hammes; Christophe Langouët-Astrie; Clayton A Smith; Brent E Palmer; Peter A Forsberg; Tomer M Mark; Craig T Jordan; Daniel W Sherbenou
Journal:  Blood Adv       Date:  2020-04-28

7.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Authors:  Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

8.  The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Authors:  Wilson I Gonsalves; Michael M Timm; S Vincent Rajkumar; William G Morice; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; David Dingli; Nelson Leung; Prashant Kapoor; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Leuk Res       Date:  2016-03-10       Impact factor: 3.156

Review 9.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

10.  Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Authors:  Surbhi Sidana; Dragan Jevremovic; Rhett P Ketterling; Nidhi Tandon; Patricia T Greipp; Linda B Baughn; Angela Dispenzieri; Morie A Gertz; Sundararajan Vincent Rajkumar; Shaji K Kumar
Journal:  Am J Hematol       Date:  2019-02-06       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.